文献速递免疫规划卫生政策与健康促进

加拿大青少年百日咳免疫策略的成本-效用分析

Assessing adolescent immunization options for pertussis in Canada: A cost-utility analysis.
PubMed 文献 · Vaccine · 2019-12-27

该研究采用疾病史模拟马尔可夫模型,从医疗 payer 视角评估加拿大青少年(10岁起)三种百白破(Tdap)接种策略的终身成本-效用。当前14岁接种策略被10岁接种和无免疫策略支配;与无免疫相比,10岁接种的增量成本-效用比为每质量调整生命年74899美元。在每质量调整生命年50000美元阈值下,取消青少年接种在78%的模拟中为最具成本-效果策略。

要点

  • 当前14岁接种Tdap策略被10岁接种和无免疫策略支配。
  • 与无免疫相比,10岁接种的ICER为每QALY 74899美元。
  • 在50000美元/QALY阈值下,取消青少年接种在78%模拟中最具成本-效果。

核心结论

  • 分析假设孕妇免疫已推荐的政策背景,结果表明替代青少年Tdap策略(10岁接种或取消青少年疫苗)比当前14岁接种更具成本-效果。

研究设计与样本

  • 成本-效用分析,使用百日咳疾病史模拟马尔可夫模型,队列为10岁起青少年。
  • 评估三种Tdap接种策略:10岁接种、取消青少年接种、14岁接种(现状)。
  • 从医疗 payer 视角,采用终身时间范围;成本和结局按每年1.5%贴现。
  • 进行确定性和概率敏感性分析以评估参数不确定性。

主要发现

  • 当前推荐的青少年免疫策略(14岁接种)平均产生40.4432期望QALYs和每人26.28美元成本。
  • 该策略被10岁接种和无免疫策略支配。
  • 与无免疫相比,10岁接种青少年的ICER为每QALY 74899美元。
  • 结果对百日咳发病率和中重度百日咳效用最敏感。
  • 在每QALY 50000美元成本-效果阈值下,取消青少年接种在78%的模拟中为最具成本-效果策略。

局限性

  • 分析假设孕妇免疫已推荐的政策背景。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Adolescent tetanus, diphtheria and pertussis (Tdap) immunization helps prevent pertussis infection. Timing of Tdap receipt represents an important facet of successful adolescent pertussis immunization. Potential strategies for timing of vaccine administration are each associated with different benefits - including disease prevention - and costs. The objective of this study was to assess the cost-utility of adolescent pertussis immunization strategies in Canada. METHODS: A cost-utility analysis was conducted using a pertussis disease history-simulating Markov model, with adolescents (beginning at age 10 years) as the cohort of interest. The model assessed three Tdap vaccination strategies: (1) immunization of 10 year olds, (2) removal of adolescent vaccination, and (3) immunization of 14 year olds (status quo). The analysis was conducted from a healthcare payer perspective and used a lifetime time horizon. Primary outcomes included life years, quality-adjusted life years (QALYs), health system costs, and an incremental cost-effectiveness ratio (ICER). Costs and outcomes were discounted at 1.5 percent annually. Deterministic and probabilistic sensitivity analyses were performed to assess parameter uncertainty. RESULTS: The current recommended adolescent immunization strategy (at age 14) resulted in an average of 40.4432 expected QALYs and $26.28 per individual. This strategy was dominated by immunization at 10 years and no immunization. Compared to no immunization, immunizing adolescents at age 10 had an ICER of $74,899 per QALY. Results were most sensitive to the incidence of pertussis and the utility of moderate or severe pertussis. At a cost-effectiveness threshold of $50,000/QALY, removal of adolescent vaccination represented the most cost-effective strategy in 78% of simulations. CONCLUSION: Analysis assumes a policy context where immunization of pregnant women is recommended. Findings suggest that alternate adolescent Tdap vaccine strategies - either immunization of 10 year olds, or removal of the adolescent vaccine - are more cost-effective than the current practice of immunizing 14 year olds.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Anyiwe K, Richardson M, Brophy J, et al. Assessing adolescent immunization options for pertussis in Canada: A cost-utility analysis. Vaccine. 2019. PMID: 31889607. doi:10.1016/j.vaccine.2019.12.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。